No Data
No Data
Perspective Gets FDA Fast Track Status for Radiopharmaceutical VMT101
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia
Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
Cellectar Biosciences: Delay in Filing 10-Q Is a Result of Company's Need to Restate Certain Previously Filed Fincl Statements >CLRB